We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PTC Therapeutics Initiates Phase II/III Study for Coronavirus
Read MoreHide Full Article
PTC Therapeutics, Inc. (PTCT - Free Report) announced that the initiation of a phase II/III study to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.
The oral medication is a novel dual-mechanism agent designed to treat viral replication and uncontrolled inflammatory response.
The study will be conducted in two stages, which will be initiated in the United States, and the company plans to conduct research among patients in Spain, Brazil and Australia.
The first stage of the study will begin with 40 enrolled patients followed by a larger cohort of approximately 340 participants. The company’s primary objective is to evaluate the clinical efficacy of PTC299 compared with placebo, assessed by time to respiratory improvement in adult individuals hospitalized with COVID-19.
According to the company, the oral, small molecule tablet inhibits the dihydroorotate dehydrogenase (DHODH) cellular enzyme, which is used to produce the RNA building blocks for the production of SARS-CoV-2.
In addition, the investigational molecule has previously demonstrated potent inhibition of viral replication in SARS-CoV-2 cell-based assays. A number of RNA viruses require the same building blocks, which is why, in preclinical tests, PTC299 has shown broad-spectrum antiviral activity.
The shares of the company increased 4.8% year to date against the industry’s decline of 6%.
PTC299 is also being developed for oncological indications. Further, the candidateis currently being studied in a clinical trial in acute myeloid leukemia (AML) patients. In a PTC299 clinical study, results showed that the candidateinhibited DHODH, confirming the mechanism of action in patients.
Meanwhile, several marketed drugs like Sanofi/Regeneron’s IL-6 inhibitor,Kevzara; Roche’s (RHHBY - Free Report) IL-6 inhibitor, Actemra; Incyte/Novartis’ JAK1/JAK2 inhibitor, Jakafi; AstraZeneca’s (AZN - Free Report) BTK inhibitor, Calquence; and Amgen’s (AMGN - Free Report) PDE4 inhibitor, Otezla, among others, are being evaluated to treat respiratory complications associated with COVID-19, which is the need of the hour.
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all. This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025. Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Image: Bigstock
PTC Therapeutics Initiates Phase II/III Study for Coronavirus
PTC Therapeutics, Inc. (PTCT - Free Report) announced that the initiation of a phase II/III study to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.
The oral medication is a novel dual-mechanism agent designed to treat viral replication and uncontrolled inflammatory response.
The study will be conducted in two stages, which will be initiated in the United States, and the company plans to conduct research among patients in Spain, Brazil and Australia.
The first stage of the study will begin with 40 enrolled patients followed by a larger cohort of approximately 340 participants. The company’s primary objective is to evaluate the clinical efficacy of PTC299 compared with placebo, assessed by time to respiratory improvement in adult individuals hospitalized with COVID-19.
According to the company, the oral, small molecule tablet inhibits the dihydroorotate dehydrogenase (DHODH) cellular enzyme, which is used to produce the RNA building blocks for the production of SARS-CoV-2.
In addition, the investigational molecule has previously demonstrated potent inhibition of viral replication in SARS-CoV-2 cell-based assays. A number of RNA viruses require the same building blocks, which is why, in preclinical tests, PTC299 has shown broad-spectrum antiviral activity.
The shares of the company increased 4.8% year to date against the industry’s decline of 6%.
PTC299 is also being developed for oncological indications. Further, the candidateis currently being studied in a clinical trial in acute myeloid leukemia (AML) patients. In a PTC299 clinical study, results showed that the candidateinhibited DHODH, confirming the mechanism of action in patients.
Meanwhile, several marketed drugs like Sanofi/Regeneron’s IL-6 inhibitor,Kevzara; Roche’s (RHHBY - Free Report) IL-6 inhibitor, Actemra; Incyte/Novartis’ JAK1/JAK2 inhibitor, Jakafi; AstraZeneca’s (AZN - Free Report) BTK inhibitor, Calquence; and Amgen’s (AMGN - Free Report) PDE4 inhibitor, Otezla, among others, are being evaluated to treat respiratory complications associated with COVID-19, which is the need of the hour.
PTC Therapeutics, Inc. Price
PTC Therapeutics, Inc. price | PTC Therapeutics, Inc. Quote
Zacks Rank
PTC Therapeuticscurrently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all. This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025. Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>